Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis

Thomas R. Collins  |  April 14, 2016

SAN FRANCISCO—The discovery of a promising new target for the treatment of osteoporosis has a beginning to the story that, when it comes to scientific breakthroughs, rings familiar: It started with a disappointment. Researchers in the lab of Laurie H. Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College—were in search…

Rheumatologist Finds Opportunity for Continual Learning in Rheumatology, Karate

Eric Butterman  |  April 13, 2016

Robert Thoburn, MD, finds discipline and the opportunity for continual learning in both rheumatology and karate, an activity he has pursued for decades. Karate Lessons “I was fortunate to have had the opportunity to learn karate and achieve a black belt,” Dr. Thoburn says. “I used my training journal and [did] extensive research to write a…

Ethics Forum: Pediatric Vaccination Refusals Raise Challenges for Physicians

Emily von Scheven, MD, MAS  |  April 13, 2016

The boy who could not walk: S.L. is a previously healthy 10-year-old boy who has not walked for three months. Physical examination reveals swollen wrists, knees, ankles and several toes. There is reduced hip range of motion and flexion contractures of both knees. He can stand with assistance, but is unable to take a single…

Rheumatology Drug Updates: Biosimilars Receive Positive News & More

Michele B. Kaufman, PharmD, BCGP  |  April 13, 2016

On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 On Jan. 16, 2016, EMA granted marketing authorization in the European Union for Benepali to be used to treat rheumatoid arthritis (RA), psoriatic…

Hidradenitis Suppurativa Can Complicate Biologic Therapy

Will Boggs, MD  |  April 13, 2016

NEW YORK (Reuters Health)—Hidradenitis suppurativa can complicate biologic therapy of chronic inflammatory diseases, according to a retrospective study from France and Belgium. Hidradenitis suppurativa (HS) often responds to treatment with biologic agents, but there have been scattered reports of patients developing HS while undergoing biologic therapy. Dr. Coline Faivre from Hôpital Edouard Herriot in Lyon,…

Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  April 13, 2016

The FDA has received an application to expand the use of etanercept to treat plaque psoriasis in pediatric patients. Boehringer Ingelheim and AbbVie have announced a collaborative partnership to develop treatments for multiple autoimmune diseases. And gerilimzumab may prove safe and effective for treating inflammatory diseases at very low doses…

Carpal Tunnel Syndrome: Is Post-Surgical Rehabilitation Helpful?

Lara C. Pullen, PhD  |  April 11, 2016

A recent research review compared the results of various studies on rehabilitation treatments, including immobilization, exercise and cold therapy, for patients with carpal tunnel syndrome after surgery. The authors concluded that little evidence supports the effectiveness of rehabilitation techniques, and many of the studies reviewed have similar limitations…

From the Expert: Don’t Forget to Vaccinate Immuncompromised Patients

Richard Quinn  |  April 8, 2016

Preventing infection in immunocompromised patients is challenging, especially with the increased use of biologic treatments, which have been known to reactivate latent infections, such as the herpes zoster virus. Nicolas Issa, MD, discusses recent vaccination research and prevention techniques to help this patient group avoid infection…

U.S., Canada Issue Joint Alert on Ransomware after Hospital Attacks

Jim Finkle  |  April 7, 2016

(Reuters)—The U.S. and Canada on Thursday issued a rare joint cyber alert, warning against a recent surge in extortion attacks that infect computers with viruses known as “ransomware,” which encrypt data and demand payments for it to be unlocked. The warning follows reports from several private security firms that they expect the crisis to worsen,…

U.S. to Raise Payments to Insurers for Medicare Advantage 2017 Plans

Caroline Humer  |  April 7, 2016

NEW YORK (Reuters)—U.S. health insurers that provide Medicare Advantage plans to elderly and disabled Americans will receive government payments in 2017 that are 0.85 percent higher on average than in 2016, reflecting small anticipated growth in medical costs, the U.S. Department of Health and Human Services said on Monday. Health and Human Services’ final plan…

  • « Previous Page
  • 1
  • …
  • 515
  • 516
  • 517
  • 518
  • 519
  • …
  • 820
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences